RGL-305+ Lymphoma + Exploratory Clinical Study

This study is an open, prospective, dose-increasing exploratory clinical trial. To evaluate the safety, cytodynamics and initial efficacy of RGL-305 in patients with lymphoma. All enrolled lymphoma patients were required to achieve CR or PR and MRD positive after standard treatment, PR patients were required to have a Deauville score of 4, and all patients would receive RGL-305 cell reinfusion therapy.

Trial Details

NCT ID
NCT07006012
Phase
NA
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • RGL-305
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntarily participate in the study and sign a written informed consent
  • Age 18-75 years old (including the boundary value), gender is not limited;
  • Patients with pathologically confirmed lymphoma who have previously received at least one standard treatment. After the last treatment, patients wi…
  • Be willing to provide blood or tissue samples required for cytodynamic and biomarker detection before and after treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →